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Background: This phase 1 study evaluated the maximum tolerated dose (MTD), safety, and efficacy of bosutinib (competitive Src/
Abl tyrosine kinase inhibitor) plus capecitabine.
Methods: Patients with locally advanced/metastatic breast, pancreatic, or colorectal cancers; cholangiocarcinoma; or
glioblastoma received bosutinib plus capecitabine at eight of nine possible dose combinations using an ‘up-down’ design to
determine the toxicity contour of the combination.
Results: Among 32 enrolled patients, none of the 9 patients receiving MTD (bosutinib 300mg once daily plus capecitabine
1000mgm
 2 twice daily) experienced dose-limiting toxicities (DLTs). Overall, 2 out of 31 (6%) evaluable patients experienced
DLTs (grade 3 neurologic pain (n¼1); grade 3 pruritus/rash and increased alanine aminotransferase (n¼1)). Most common
treatment-related adverse events (AEs) were diarrhoea, nausea, vomiting, palmar-plantar erythrodysesthesia (PPE), fatigue; most
frequent grade 3/4 AEs: PPE, fatigue, and increased alanine/aspartate aminotransferase. Although diarrhoea was common, 91% of
affected patients experienced maximum grade 1/2 events that resolved. Best overall confirmed partial response or stable disease
424 weeks (all tumour types) was observed in 6 and 13% of patients.
Conclusions: In this population of patients with advanced solid tumours, bosutinib plus capecitabine demonstrated a safety
profile similar to that previously reported for bosutinib or capecitabine monotherapy; limited efficacy was observed.
Advanced solid tumours are commonly treated with chemother-
apeutic agents, including capecitabine, an oral 5-fluorouracil
(5-FU) prodrug that induces cell death by inhibiting thymidylate
synthase (TS; Koukourakis et al, 2008; XELODA Full Prescribing
Information, 2013). Capecitabine monotherapy has shown efficacy
in metastatic colorectal cancer (overall response rate (ORR): 19%;
Van Cutsem et al, 2001) and in metastatic breast cancer (ORR:
15–28%; Blum et al, 1999, 2001; Reichardt et al, 2003; Fumoleau
et al, 2004; Amari et al, 2010; Blum et al, 2012). However,
resistance to 5-FU, which is mediated primarily by TS upregula-
tion, has been observed in several solid tumour models (Beck et al,
1994; Johnston et al, 1995; Peters et al, 2002).
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nonreceptor tyrosine kinase Src (Summy and Gallick, 2003;
Parsons and Parsons, 2004), synergises with 5-FU to restore
chemosensitivity in pancreatic cancer cells (Ischenko et al, 2008)
and to increase cytotoxicity in breast cancer models (Somlo et al,
2013). In addition, a study in non–small-cell lung cancer cells
showed synergistic cytotoxic effects with the combination of the
Src inhibitor dasatinib and the TS-inhibitor pemetrexed and
demonstrated that pemetrexed-induced TS upregulation is blocked
via Src inhibition; notably, in that study, pretreatment TS levels
were positively correlated with Src levels, and increased Src and TS
levels were significantly correlated with poorer survival in the
donor patients (Ceppi et al, 2012). These findings suggest a
potential role for the combination of a TS inhibitor and a Src
inhibitor in countering 5-FU resistance.
Src has been recognised as a potential therapeutic target in a
number of solid tumour settings, as Src dysregulation promotes
tumour progression, metastasis, invasion, and angiogenesis
(Talamonti et al, 1993; Verbeek et al, 1996; Summy and Gallick,
2003; Trevino et al, 2006; Park et al, 2007; Finn, 2008; Guarino,
2010; Gleixner et al, 2011). Src inhibition has been shown to exert
antitumour activity in cellular and xenograft models of breast
cancer (Finn et al, 2007; Huang et al, 2007; Jallal et al, 2007) and to
exert antitumour and anti-invasive activity in colon (Golas et al,
2005; Serrels et al, 2006), head and neck (Johnson et al, 2005; Song
et al, 2013), prostate (Nam et al, 2005), non–small-cell lung
(Johnson et al, 2005), glioblastoma (Du et al, 2009), and sarcoma
(Shor et al, 2007) cancers in preclinical studies.
Dasatinib and bosutinib are dual inhibitors of the Src and Abl
tyrosine kinases (Mayer and Krop, 2010). An initial phase 1 study
has evaluated the combination of dasatinib (100–140mg daily)
with capecitabine (800–1000mgm
 2 twice daily) in advanced
breast cancer (n¼52), resulting in an ORR of 22% and manageable
tolerability (Somlo et al, 2013). Although the ORR was similar to
that reported with capecitabine monotherapy in other studies
(Blum et al, 1999, 2001; Reichardt et al, 2003; Fumoleau et al, 2004;
Amari et al, 2010), the phase 1 study was not powered sufficiently
to assess the efficacy contributions of dasatinib to the combination
(Somlo et al, 2013), suggesting that further evaluation of Src
inhibitors in combination with capecitabine is needed.
Bosutinib (SKI-606), which is approved in the United States
(Bosulif Full Prescribing Information, 2013) and Europe (Bosulif
Summary of Product Characteristics, 2013) for use in Philadelphia
chromosome-positive chronic myeloid leukaemia, has been shown
to inhibit Src and the growth of pancreatic tumour xenografts
(Messersmith et al, 2009), the migration and invasion of breast
cancer cells (Vultur et al, 2008), and the growth and invasion of
prostate cancer cells and xenografts (Rabbani et al, 2010) in
preclinical models. In addition, bosutinib at a dose of 400mg per
day has shown limited activity (ORR: 5.5%; median progression-
free survival (PFS): 9.9 weeks) and a manageable tolerability profile
in a phase 2 study of patients (n¼73) with unselected, heavily
pretreated advanced breast cancer (67% hormone receptor-
positive; Campone et al, 2012). Together, these preclinical and
preliminary clinical findings support the feasibility of evaluating
the combination of bosutinib and capecitabine in patients with
select locally advanced or metastatic solid tumours. In the present
study, the maximum tolerated dose (MTD) and the safety,
tolerability, and antitumour activity of this combination are
assessed in patients with advanced solid tumours.
MATERIALS AND METHODS
Study design. This study was originally planned as a phase 1/2,
multicentre, open-label study (ClinicalTrials.gov; Unique ID:
NCT00959946); the phase 1 portion was completed and the results
are reported here. The phase 1 study used an ‘up-down’ dose-
escalation design (Ivanova and Wang, 2004) to determine the
MTD of bosutinib plus capecitabine combination therapy in
patients with selected solid tumours. The results of a simulation
study showed that, compared with a specific 3þ3 design, this
‘up-down’ dose-escalation design allows more patients to be
evaluated closer to the MTD and fewer at toxic dose levels (see
Supplementary Materials). Bosutinib was administered orally once
daily continuously, and capecitabine was administered orally twice
daily on days 1 to 14 of each 21-day treatment cycle. Up to nine
dose combinations, including three dose levels of bosutinib (200,
300, and 400mg) and three dose levels of capecitabine (625, 750,
and 1000mgm
 2), were selected as possible dose levels. The initial
dose cohorts with two patients each were (i) bosutinib 200mg per
day plus capecitabine 750mgm
 2 twice daily and (ii) bosutinib
300mg per day plus capecitabine 625mgm
 2 twice daily.
Additional cohorts could be enrolled at higher or lower dose
levels based on the number of dose-limiting toxicities (DLTs;
described below) observed during the first 21 days in the current
cohort of two patients, the cumulative toxicity rate at that dose
combination, and the current doses of bosutinib and capecitabine.
Cohort enrollment was based on the rules presented in Table 1 (see
Supplementary Materials for additional information). The
‘up-down’ dose-escalation design allowed up to nine dose
combinations across the two drugs studied (Table 2). This design
would also allow the possibility of achieving two concurrent MTD
levels, one that would maximise bosutinib and the other that would
maximise capecitabine, in the event that increasing both
concurrently proved untenable. Patients were enrolled at the next
dose level when two evaluable patients at the same dose level had
been evaluated for the first 21-day treatment cycle and had
received at least 14 doses of bosutinib and at least 10 doses of
capecitabine or experienced a DLT, whichever occurred first, until
a total of 24 evaluable patients were assessed. If a patient withdrew
from the study before completing the 21-day period without
experiencing a DLT, another patient was enrolled to replace that
patient at the current dose combination.
DLTs were defined as any of the following treatment-related
events that occurred during the first 21-day cycle: grade 3/4 non-
haematologic adverse event (AE), including nausea, vomiting, or
diarrhoea despite optimal medical therapy, and asthenia lasting more
than 3 days; grade 4 haematologic AE; or delayed recovery from one
of the above AEs, causing delay of treatment by at least 3 weeks.
Table 1. Cohort enrollment rules
Number of
DLTs in current
cohort
a
Cumulative
toxicity rate Next enrollees
0 o33% 2 Patients at 1 level higher for
bosutinib (capecitabine unchanged)
2 patients at 1 level higher for
capecitabine (bosutinib unchanged)
0 X33% 2 Patients at 1 level lower for
bosutinib and 1 level higher for
capecitabine
1o r2 o33% 2 Patients at 1 level higher for
bosutinib and 1 level lower for
capecitabine
1o r2 X33% If the current bosutinib level 4
capecitabine, 2 subjects at 1 level
lower bosutinib (capecitabine
unchanged). Otherwise, 2 subjects
at 1 level lower capecitabine
(bosutinib unchanged)
Abbreviation: DLT¼dose-limiting toxicity.
aOut of two patients.
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dose level at which less than 33% of patients experienced a DLT.
Written informed consent was obtained from all patients before
enrollment. The protocol was reviewed and approved by the Ethics
Committees/Institutional Review Boards of the participating institu-
tions, and the study was conducted according to the Declaration of
Helsinki and European Good Clinical Practice requirements.
Eligibility criteria. Eligible patients were men and women aged
X18 years with a confirmed pathologic diagnosis of locally advanced
or metastatic breast cancer, pancreatic cancer, colorectal cancer,
cholangiocarcinoma, or glioblastoma that was not curable with
approved regimens. Patients were also required to have at least one
radiologically measurable lesion as defined by the Response
Evaluation Criteria In Solid Tumors (RECIST), version 1.0, and an
Eastern Cooperative Oncology Group Performance Status score of 0
to 2. Bone or skin could not be the only site of disease, and patients
with clinically unstable primary or metastatic central nervous system
tumours were ineligible. No prior treatment with Src inhibitors was
permitted; however, prior treatment with capecitabine or 5-FU was
allowed unless stopped for toxicity. No chemotherapy, investigational
therapy, major surgery, or radiation therapy within 14 days of study
treatment initiation was allowed. Patients with any other major
illness, including a history of clinically significant or uncontrolled
cardiac disease, serious active infection, uncontrolled major seizure
disorder, or significant pulmonary disorder, were ineligible.
Safety and efficacy assessments. The primary safety objective was
to determine the MTD of bosutinib plus capecitabine in patients with
solid tumours by examining the DLT rates within the dose cohorts. All
patients who received at least one dose of study treatment were
included in the safety evaluation, which included the incidence of AEs,
physical examination, laboratory evaluations, 12-lead electrocardio-
gram, and left ventricular ejection fraction measurement. Safety events
were graded for severity according to the National Cancer Institute
Common Terminology Criteria for Adverse Events, version 3.0.
Tumour assessments were performed for all patients at screen-
ing, and response was assessed every 6 weeks until disease
progression or treatment discontinuation. No primary efficacy end
point was specified; the secondary objective of antitumour activity
was assessed based on best confirmed overall response according to
RECIST version 1.0 (Therasse et al, 2000) and ORR (confirmed
complete response (CR) or partial response (PR)).
RESULTS
Patients. A total of 32 patients were enrolled in this phase 1 study
between October 2009 and March 2011, among whom, the median
age was 62 (range, 42–82) years (Table 3). The majority of patients
had a diagnosis of colorectal cancer (44%), breast cancer (34%), or
pancreatic cancer (16%); cholangiocarcinoma and glioblastoma
were each present in one patient. Most (69%) patients had
previously received at least five antitumour treatment regimens for
locally advanced or metastatic disease; 22% of patients had
previously received capecitabine treatment.
The median study duration was 81.0 days (range, 22–420 days),
with a median duration of treatment of 63.5 days (range, 19–419
days). All patients discontinued the study, the primary reasons for
which included disease progression (n¼26 (81%)), AEs (n¼4
(13%)), death (n¼1 (3%)), and patient withdrawal (n¼1 (3%)).
Determination of the MTD. Because of the adaptive nature of the
study design, all possible dose combinations shown in Table 2 were
explored at least once, with the exception of bosutinib 400mg per
day plus capecitabine 625mgm
 2 twice daily. The sequence of
patient enrollment in each dose-escalation cohort is shown in
Table 4. Based on the observed toxicity, the MTD was determined to
be bosutinib 300mg per day plus capecitabine 1000mgm
 2 twice
daily on days 1–14 of each 21-day treatment cycle, with no DLTs
observed for the two patients treated at the MTD during the dose-
escalation phase. An additional seven patients were subsequently
Table 2. Dose combinations for determination of the MTD
Bosutinib, mg per day
Capecitabine, mgm
 2 twice daily 200, n 300, n 400, n
1000 4 9
a,b 2
c
750 4
d 42
c
625 2 5
d,e
Abbreviations: DLT¼dose-limiting toxicity in patients who experienced a DLT within the
first 21 days of treatment, regardless of the number of treatment doses received, or in
patients who received X14 doses of bosutinib and X10 days of capecitabine in the first 21
days of treatment; MTD¼maximum tolerated dose (shaded in table); n¼total number of
patients enrolled at each dose combination.
aBased on the DLTs, the MTD was determined to be bosutinib 300mg per day plus
capecitabine 1000mgm
 2 (which is shaded in the table). No DLTs were observed at the
MTD dose level.
bTwo patients were initially enrolled at the MTD level, for a total of 24 patients included in
the initial DLT evaluation; an additional seven patients were subsequently enrolled at this
dose level to allow further evaluation and confirmation of the MTD.
cDLTs were observed in 1 (50%) patient in the bosutinib 400mg per day plus capecitabine
1000mgm
 2 group (grade 3 alanine aminotransferase and pruritus/rash) and 1 (50%)
patient in the bosutinib 400mg per day plus capecitabine 750mgm
 2 group (grade 3
neurologic pain).
dInitial dose cohorts investigated.
eOne of the five patients treated at this dose level was excluded from the DLT evaluation
because of no DLT and failure to receive X14 doses of bosutinib or X10 doses of
capecitabine.
Table 3. Patient demographic and baseline disease
characteristics
Characteristic N¼32
Age (years)
Median (range) 62 (42–82)
Sex, n (%)
Women 18 (56)
Men 14 (44)
Race, n (%)
White 24 (75)
Asian 7 (22)
Black/African American 1 (3)
ECOG performance status,
a n (%)
0 20 (63)
1 12 (38)
Tumour type, n (%)
Colorectal cancer 14 (44)
Breast cancer 11 (34)
Pancreatic cancer 5 (16)
Cholangiocarcinoma 1 (3)
Glioblastoma 1 (3)
No. of prior regimens in the locally advanced or metastatic
setting
0 1 (3)
1 4 (13)
2 1 (3)
3 1 (3)
4 3 (9)
X5 22 (69)
Prior capecitabine treatment
n (%) 7 (22)
Abbreviation: ECOG¼Eastern Cooperative Oncology Group.
aPercentages may not total 100% because of rounding.
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were observed. Only one MTD was identified for this combination.
Overall, 2 out of 31 (6%) evaluable patients experienced DLTs.
The first patient was a 56-year-old woman with metastatic breast
cancer who was receiving bosutinib 400mg per day plus capecitabine
750mgm
 2 twice daily and experienced grade 3 neurologic pain on
study day 5. Bosutinib 400mg per day was stopped on study day 8
and bosutinib 300mg per day was started on study day 14, after the
neurologic pain resolved to grade 1. The second patient was a 58-
year-old woman with metastatic breast cancer who was receiving
bosutinib 400mg per day plus capecitabine 1000mgm
 2 twice daily
who experienced grade 3 increased alanine aminotransferase (ALT)
and pruritus/rash, both of which resolved following temporary
discontinuation of bosutinib. These DLTs were considered to be
treatment related; association with either bosutinib or capecitabine
treatment was not determined. One additional patient receiving
bosutinib 200mg per day plus capecitabine 1000mgm
 2 twice daily
experienced grade 2 fatigue, which later progressed to grade 4
severity one day after the 21-day DLT assessment period; because
of this timing the event did not meet the DLT criteria. The
recommended MTD of the combination would not have changed if
this subject met the DLT criteria. Notably, DLTs resolved after
temporarily stopping treatment and none of these events were
considered by the investigators to be serious AEs.
Safety and tolerability. All 32 (100%) patients experienced at least
one treatment-emergent AE among whom 29 (91%) experienced at
least one treatment-related (bosutinib and/or capecitabine) AE. The
most common treatment-related AEs, overall as well as within the
MTD cohort, were diarrhoea, nausea, palmar-plantar erythrody-
sesthesia (PPE), fatigue, and vomiting (Table 5). A total of 15 (47%)
patients experienced at least one grade 3/4 treatment-related AE,
most frequently PPE, increased ALT, and increased aspartate
aminotransferase (AST; Table 5). Ten (31%) patients experienced
at least one serious AE, including anaemia, atrial fibrillation,
constipation, gastrointestinal obstruction, asthenia, chest pain,
hemiparesis, renal impairment, acute respiratory distress syndrome,
dyspnoea (n¼1e a c h ) ;b r o n c h i t i s( n¼2), and disease progression
(glioblastoma multiforme (n¼1), malignant neoplasm (n¼2);
pancreatic cancer (n¼1)).
Although diarrhoea was common (n¼23 (72%)), 91% (21 out
of 23) of patients with diarrhoea experienced only maximum grade
1 or 2 events, all patients had their diarrhoea resolved (median
(range) cumulative duration of 10 (1–267) days), and no patient
discontinued treatment because of diarrhoea, suggesting that
events were manageable. Two (9%) patients required dose
interruption, and one (4%) patient had dose reduction in order
to manage their diarrhoea events. Treatment-emergent AEs of
grade 3/4 ALT or AST elevations were reported in three (9%) and
three (9%) patients, respectively; these events were managed by
dose interruption in two and two patients, respectively, and all
resolved with no patient discontinuing treatment. Treatment-
related haematologic AEs were relatively uncommon, with one
patient each experiencing maximum grade 1 or 2 leukopenia,
lymphopenia, neutropenia, and thrombocytopenia. Cardiac events
were reported in five (16%) patients; four of these subjects with
events considered drug related, one of which was a serious AE of
atrial fibrillation observed in a patient with a history of peripheral
arterial occlusive disease and hypertension, who was receiving
Warfarin. Prolonged QT (grade 2) was reported in two patients,
and decreased ejection fraction (grade 3) was reported in one
patient; all had a prior history of cardiac disease. Most of the
resolved cardiac events were transient, with cumulative median
(range) duration of 16 (10–22) days, and all but one of the patients
(grade 3 decreased ejection fraction) had their cardiac events
resolve. Cumulative duration for this patient is unknown.
Grade 3/4 laboratory values were reported in nine (28%)
patients on treatment, and included abnormal sodium values
Table 4. The sequence of patient enrollment in each dose-escalation cohort
a
Cohort
Sequence
of cohort
enrollment
Dose level
(CAPE (mgm
 2)/
BOS (mg)) Number
Patients
enrolled, n
Patients
evaluable
for DLT, n DLT
Next
dose cohort
1 750/200 C1 2 2 None C3/C4
2 625/300 C2 3
b 2 None
c C7
3 750/300 C3 2 2 None C5/C6
4 1000/200 C4 2 2 None C8
d
5 750/400 C5 2 2 1 DLT: Grade 3 neurologic pain C9
6 1000/300 C6 2 2 None C10
7 625/200 C7 2 2 None C11/C12
8 750/300 C9 2 2 None NA
e
9 1000/200 C8 2 2 None
f NA
10 1000/400 C10 2 2 1 DLT in 1 patient:
Grade 3 ALT increased
Grade 3 itchy skin
Grade 3 skin rash
11 750/200 C11 2 2 None NA
e
12 625/300 C12 2 2 None NA
e
Abbreviations: AE¼adverse event; ALT¼alanine aminotransferase; BOS¼bosutinib; C¼cohort; CAPE¼capecitabine; DLT¼dose-limiting toxicity; NA, not applicable.
aData snapshot date: 06 July 2011.
bOne patient was not evaluable for DLTs and was replaced.
cA DLT occurred in Cohort 2 at the time enrollment in Cohort 7 was initiated; however, during subsequent review, the corresponding AE (grade 3 ALT increased) was not deemed to be a DLT.
dAfter completion of Cohort 4, two additional patients were enrolled in Cohort 8 (same dose level) per protocol because Cohort 6 was already enrolling.
eEnrollment in subsequent cohorts after Cohort 8 was not required because enrollment of 24 evaluable patients had been completed as the last patient finished Cohort 8.
fA DLT occurred in Cohort 8; however, during subsequent review, the corresponding AE (grade 4 fatigue) was deemed not a DLT during a subsequent review. This DLT did not affect cohort
enrollment as 24 subjects had already been enrolled when C8 was finished.
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time, phosphorous, calcium, ALT, and prothrombin time (n¼2
each); and glucose, AST, and haemoglobin (n¼1 each). Grade 3/4
partial thromboplastin time and prothrombin time increases were
reported in one patient both at baseline and on treatment. Based
on electrocardiogram laboratory data, no patient had a QT or
corrected QT (QTc) interval greater than 500ms.
Bosutinib and capecitabine dose modifications due to AEs are
shown in Table 5. Bosutinib dose reduction and interruption due
to an AE occurred in 9% and 34% of patients, respectively.
Capecitabine dose reduction and interruption due to an AE occurred
in 13% and 50% of patients, respectively. Four (13%) patients
experienced AEs that led to treatment discontinuation; AEs included
right hemiparesis (due to disease progression that led to death) and
asthenia (n¼1), fatigue (n¼1), bronchitis (that led to death) and
acute respiratory distress syndrome (n¼1), and PPE syndrome
(n¼1). In addition, three other patients had AEs related to disease
progression that led to treatment discontinuation, reported as
malignant neoplasm (n¼2) and glioblastoma multiforme (n¼1).
Of the AEs that led to treatment discontinuation, only PPE and
fatigue were considered treatment related.
Overall, six (19%) deaths occurred during the study, with five
deaths occurring within 28 days of the last study dose. Five of the
six deaths were due to disease progression (primary diagnoses of
pancreatic cancer (n¼2); breast cancer, glioblastoma multiforme,
and colorectal cancer (n¼1 each)), whereas the other was due to
an unrelated AE of bronchial infection (n¼1). None of the deaths
were considered drug related.
Antitumour activity. Among the intent-to-treat population
(n¼32), one patient with breast cancer and one patient with
colorectal cancer achieved a confirmed PR; no patient achieved a
Table 5. Treatment-related AEs and treatment modifications and discontinuations due to AEs
MTD cohort (n¼9) All patients (N¼32)
Treatment-related AEs Any grade Grade 3/4 Any grade Grade 3/4
Any AE,
a n (%) 9 (100) 4 (44) 29 (91) 15 (47)
Diarrhoea 8 (89) 0 21 (66) 2 (6)
Nausea 4 (44) 0 13 (41) 0
PPE 3 (33) 1 (11) 10 (31) 3 (9)
Fatigue 4 (44) 0 9 (28) 2 (6)
Vomiting 2 (22) 0 8 (25) 0
Decreased appetite 2 (22) 0 5 (16) 0
Increased ALT 2 (22) 1 (11) 4 (13) 3 (9)
Mucosal inflammation 2 (22) 0 4 (13) 0
Increased AST 2 (22) 2 (22) 3 (9) 3 (9)
Rash 1 (11) 0 3 (9) 1 (3)
Constipation 1 (11) 0 3 (9) 0
Gastroesophageal reflux disease 0 0 3 (9) 0
Pain in extremity 0 0 2 (6) 0
Peripheral sensory neuropathy 0 0 3 (9) 0
Dyspnoea 0 0 2 (6) 1 (3)
Abdominal pain 1 (11) 0 4 (13) 0
Dry skin 0 0 2 (6) 0
Headache 1 (11) 0 2 (6) 0
Flatulence 1 (11) 0 2 (6) 0
Electrocardiogram QT prolonged 0 0 2 (6) 0
Decreased ejection fraction 1 (11) 1 (11) 1 (3) 1 (3)
Hypophosphatemia 1 (11) 1 (11) 1 (3) 1 (3)
Atrial fibrillation 0 0 1 (3) 1 (3)
Chest pain 0 0 1 (3) 1 (3)
Hypersensitivity 0 0 1 (3) 1 (3)
Neuralgia 0 0 1 (3) 1 (3)
Pruritus 0 0 1 (3) 1 (3)
Treatment modifications and
discontinuations due to AEs, n (%) MTD cohort (n¼9) All patients (N¼32)
Dose reduction
Bosutinib 1 (11) 3 (9)
Capecitabine 1 (11) 4 (13)
Dose interruption
Bosutinib 3 (33) 11 (34)
Capecitabine 4 (44) 16 (50)
Discontinuation
Discontinued treatment
b 1 (11) 4 (13)
Abbreviations: AE¼adverse event; ALT¼alanine aminotransferase; AST¼aspartate aminotransferase; MTD¼maximum tolerated dose; PPE¼palmar-plantar erythrodysesthesia.
aIncludes all treatment-related grade 3/4 AEs as well as all treatment-related AEs of any grade reported for X2 patients or for which at least one report was a grade 3/4 AE.
bAEs leading to treatment discontinuation include right hemiparesis (due to disease progression that led to death) and asthenia (n¼1), fatigue (n¼1), bronchitis (that led to death) and acute
respiratory distress syndrome (n¼1), and PPE (n¼1). In addition, three other patients had AEs related to disease progression that led to treatment discontinuation, reported as malignant
neoplasm (n¼2) and glioblastoma multiforme (n¼1).
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weeks was observed in 10 patients (breast cancer (n¼3); colorectal
cancer (n¼7)); SD lasting 424 weeks was observed in an
additional 4 patients (breast cancer (n¼2); colorectal cancer
(n¼2)). None of the patients with pancreatic cancer, cholangio-
carcinoma, or glioblastoma achieved a response or SD. A total of
15 patients (cholangiocarcinoma (n¼1); colorectal cancer (n¼4);
breast cancer (n¼5); and pancreatic cancer (n¼5)) had a best
response of progressive disease. The response status of the patient
with glioblastoma was indeterminate because the patient did not
have any post-baseline tumour assessments and discontinued
treatment before their week 6 assessment because of an AE.
DISCUSSION
The primary purpose of this study was to determine the MTD of
bosutinib plus capecitabine in patients with select locally advanced
or metastatic solid tumours. The MTD of this treatment
combination was bosutinib 300mg per day plus capecitabine
1000mgm
 2 twice daily on days 1–14 of each 21-day cycle.
A challenge in developing combination regimens incorporating
a novel agent is whether the chemotherapy dose should be
maximised with increasing doses of the novel agent, or whether the
novel agent should be maximised with increasing doses of
chemotherapy. The ‘up-down’ design allows for both possibilities
to be explored, with the possibility of achieving up to three MTD
levels for the combination. A similar ‘up-down’ design was used in
a recent phase 1 study to evaluate the MTD of neratinib in
combination with temsirolimus in patients with solid tumours
(Gandhi et al, 2014).
The 3þ3 design is the most common method for dose
evaluation in phase 1 studies and has the advantages of ease of
implementation and interpretation, together with the requirement
for smaller numbers of patients (Le Tourneau et al, 2009; Liu et al,
2013). However, drawbacks of this method include the need for a
large number of dose escalation steps (e.g., X6 dose levels) and
treatment of many patients at subtherapeutic doses, as well as
uncertainty surrounding the recommended phase 2 dose identified
(Le Tourneau et al, 2009). In contrast, the ‘up-down’ design used in
the present study allows for exploration of more dose combina-
tions. Although the ‘up-down’ design allows for a more definitive
identification of the MTD, the additional dose combinations
evaluated require enrollment of additional patients. The simulation
study also demonstrated that, compared with a specific 3þ3
design, more patients are evaluated closer to the MTD and fewer
patients at toxic dose levels using the ‘up-down’ design. Moreover,
the ‘up-down’ design mitigates the underestimation of the MTD
that is associated with the 3þ3 design.
Notably, the MTD for bosutinib (300mg per day) in combina-
tion with capecitabine in this study is lower than the therapeutic
dose identified for bosutinib monotherapy in previous studies—
500mg per day in patients with chronic/advanced phase CML
(Cortes et al, 2011, 2012) and 400mg per day in patients with
advanced solid tumours (Daud et al, 2012). In addition, the MTD
identified for capecitabine (1000mgm
 2 twice daily) in this study
is lower than the 1250mgm
 2 twice-daily dose recommended by
the US Food and Drug Administration for metastatic breast cancer
(XELODA Full Prescribing Information, 2013). However, retro-
spective analysis of medical and pharmacy records from 141
patients with metastatic breast cancer treated with capecitabine
1250mgm
 2 twice daily demonstrated greater toxicity at that dose
than previously reported in clinical studies, supporting a starting
dose of 1000mgm
 2 twice daily (Hennessy et al, 2005). Thus, the
MTD dose of capecitabine identified in the current study
(1000mgm
 2 twice daily) may be better aligned with clinical
practice than the 1250mgm
 2 twice-daily dose, and it is within
the range of doses (1000–1250mgm
 2 twice daily) recommended
by the National Comprehensive Cancer Network (National
Comprehensive Cancer Network, 2014).
In the present study, the combination of bosutinib and
capecitabine (all dose combinations) was well tolerated, which
might reflect the fact that 88% of patients received bosutinib at doses
lower than 400mg per day and 53% received capecitabine at a dose
lower than 1000–1250mgm
 2 twice daily. Comparing AE
incidence between the MTD cohort (n¼9) and all patients
excluding those receiving the MTD (n¼23), incidence was
increased in MTD-treated patients for AEs commonly reported
with bosutinib (i.e., diarrhoea, 89% vs 57%; increased ALT, 22% vs
9%; increased AST, 22% vs 4%), suggesting efficient selection of the
MTD for bosutinib. In contrast, the most frequent AE reported with
capecitabine across clinical trials—PPE (i.e., hand-foot syndrome)—
was not elevated in patients receiving the MTD versus all other
patients (33% vs 30%); it is unclear whether assessment of a higher
dose of capecitabine (e.g., 1250mgm
 2 twice daily) in the present
study would have yielded different outcomes.
Consistent with the known AE profiles for bosutinib and
capecitabine monotherapy, the AE profile of the combination of
bosutinib and capecitabine was characterised mostly by mild
gastrointestinal events (diarrhoea, nausea, vomiting), PPE, and
fatigue. Grade 3/4 ALT and AST elevations were reported in o10%
of patients, and were manageable with no patient discontinuing
treatment because of these AEs. The toxicity profile previously
observed for bosutinib monotherapy in phase 1 and 2 studies in
solid tumours was also generally characterised by mild gastro-
intestinal events that occurred early during treatment, and manage-
able ALT and AST elevations (Campone et al,2 0 1 2 ;D a u det al,
2012). Capecitabine has a well-established toxicity profile that is
primarily characterised by high incidences of PPE, diarrhoea,
nausea, vomiting, and stomatitis (Hennessy et al, 2005). Comparing
the incidences of treatment-related AEs in the present study with
those previously published for capecitabine monotherapy at a dose
of 2510mgm
 2 daily in patients with paclitaxel-refractory meta-
static breast cancer (Blum et al, 1999), certain treatment-related AEs
occurred at lower incidence in the present study (all patients),
including PPE (31% vs 56%), nausea (41% vs 52%), and vomiting
(25% vs 37%), whereas diarrhoea occurred at a higher rate in the
present study (66% vs 54%). Notably, PPE events were not observed
in studies evaluating bosutinib as monotherapy (Campone et al,
2012; Daud et al, 2012); thus, the occurrence of PPE events in the
current study was likely attributable to capecitabine administration
(XELODA Full Prescribing Information, 2013).
The tolerability results in this study are comparable with those
seen in a phase 1 study designed to identify DLTs and the
recommended phase 2 doses of dasatinib (another dual Abl/Src
TKI) plus capecitabine in women with advanced breast cancer
(Somlo et al, 2013). Consistent with the current study, some of the
most common toxicities associated with dasatinib plus capecitabine
observed in that study were gastrointestinal events (nausea,
vomiting, and diarrhoea), PPE, headache, fatigue, and asthenia
(Somlo et al, 2013). Moreover, the overall rate of treatment-related
grade 3/4 AEs reported here for bosutinib plus capecitabine (47%)
is also consistent with those reported for dasatinib plus
capecitabine (50%; Somlo et al, 2013).
The observed efficacy results should be considered limited,
given the lack of a prespecified efficacy end point and the small
number of patients evaluated at the MTD (n¼9). In this study,
two patients (breast cancer, n¼1; colorectal cancer, n¼1)
achieved a confirmed PR while receiving capecitabine at a lower
dose than MTD (750mgm
 2 twice daily) plus bosutinib 300mg
per day. A phase 1 study of bosutinib monotherapy administered
over a range of escalating doses in patients with advanced solid
tumours demonstrated a confirmed PR in one patient with breast
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and SD in five patients with colorectal or lung cancer lasting 22–50
weeks (Daud et al, 2012). In a phase 2 clinical study of single-agent
bosutinib 400mg per day in heavily pretreated patients with
advanced breast cancer unselected for hormone receptor status, four
patients achieved a confirmed PR; each of these four patients had
hormone receptor-positive breast cancer (Campone et al,2 0 1 2 ) .
Studies of single-agent capecitabine 1250mgm
 2 twice daily for
the treatment of patients with advanced or metastatic breast cancer
have reported ORRs ranging from 15 to 28% and SD rates (any
duration) ranging from 30 to 46% (Blum et al, 1999, 2001; Reichardt
et al, 2003; Fumoleau et al, 2004; Amari et al, 2010). Patients with
metastatic breast cancer treated with dasatinib plus capecitabine also
achieved some clinical benefit in a phase 1 trial, as reflected by an
ORR of 22% and an additional 30% experiencing SD lasting more
than 24 weeks (Somlo et al, 2013). The overall SD rate of 50%
observed for dasatinib plus capecitabine is consistent with the overall
SD rate with bosutinib plus capecitabine observed here (44%). In
contrast, the ORR of 22% reported for the dasatinib plus
capecitabine combination (Somlo et al, 2013) is higher than the
ORR reported for capecitabine plus bosutinib reported here (6%;
Somlo et al, 2013). The observation that none of the patients with
pancreatic cancer in this study achieved a CR or PR with bosutinib
plus capecitabine treatment might be expected based on the results
of a previous phase 2 study showing that only 3 of 41 patients
receiving single-agent capecitabine for pancreatic cancer achieved a
PR (ORR, 7%; Cartwright et al, 2002). However, comparisons of
response rates across these studies are complicated by variations in
study design and in patients’ baseline characteristics. For example,
the current study was a phase 1 study with a limited number of
breast cancer patients, most of whom had received substantial
amounts of prior therapy, and who had received capecitabine doses
lower than those associated with single-agent efficacy (1250mgm
 2
twice daily; XELODA Full Prescribing Information, 2013).
The identification of patient subgroups most likely to benefit
from therapy represents one of the major challenges in the
development of novel targeted therapies in breast and other
cancers; a number of clinical studies are currently ongoing to assess
biomarkers predictive of response to dasatinib and other Src
inhibitors in advanced solid tumours (Puls et al, 2011). For
example, a phase 1 study of dasatinib in combination with
capecitabine, oxaliplatin, and bevacizumab in patients with color-
ectal cancer showed that high expression levels of activated Src are
predictive of improved response (Strickler et al, 2013). However,
these studies are generally limited by the difficulties in assessing
correlations between biomarker levels with response, given the
small numbers of treatment responders (Strickler et al, 2013).
In conclusion, the combination of bosutinib plus capecitabine
was associated with a manageable safety profile, which was primarily
characterised by mild gastrointestinal events and similar to that
previously observed for bosutinib or capecitabine monotherapy.
Evidence supporting the efficacy of bosutinib plus capecitabine in
patients with advanced solid tumours is limited; rigorous evaluation
of the efficacy of bosutinib combined with capecitabine or with other
agents for the treatment of advanced solid tumours, including breast
cancer, awaits a suitably powered randomised clinical trial recruiting
patients selected on the basis of Src inhibitor biomarkers that may
optimise their treatment response.
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